Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 4/20 | 0.39 |
| ▸ | LCAT | P04180 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118732 | 0.88 | GRM5 (0.44) | GRM5ALDH1A1 | |
| SCHEMBL5129720 | 0.85 | LMNA (0.44) | GRM5MAPTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL5129798 | 0.84 | GRM5 (0.43) | GRM5 | |
| SCHEMBL5121780 | 0.84 | GRM5 (0.41) | GRM5ALDH1A1TRPV1 | |
| SCHEMBL5118172 | 0.84 | GRM5 (0.47) | GRM5 | |
| SCHEMBL5123999 | 0.83 | ALDH1A1 (0.46) | GRM5MAPTALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5119696 | 0.82 | ALDH1A1 (0.50) | GRM5KDM4EALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL5127910 | 0.81 | GRM5 (0.43) | GRM5MAPTALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5114859 | 0.81 | GRIN2B (0.41) | GRM5LCATHRH3 | |
| SCHEMBL5129125 | 0.79 | GRM5 (0.43) | GRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | ADRB1 497/4885FFAR4 667/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.